Stock Events

Liquidia 

$11.62
51
+$0.16+1.4% Today

Statistics

Day High
11.64
Day Low
-
52W High
16.99
52W Low
5.71
Volume
436,064
Avg. Volume
921,482
Mkt Cap
887.93M
P/E Ratio
-7.31
Dividend Yield
-
Dividend
-

Earnings

13MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.54
-0.36
-0.18
0
Expected EPS
-0.32
Actual EPS
-0.54

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LQDA. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Innoviva
INVA
Mkt Cap1.07B
Innoviva focuses on the development and commercialization of pharmaceuticals, directly competing in the respiratory and pulmonary market similar to Liquidia's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Vertex Pharmaceuticals is involved in creating therapies for cystic fibrosis, a direct competition to Liquidia's pulmonary disease treatments.
GSK
GSK
Mkt Cap81.55B
GlaxoSmithKline produces a wide range of pharmaceuticals, including treatments for respiratory diseases, directly competing with Liquidia's product offerings.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca is a global biopharmaceutical company focusing on various therapeutic areas, including respiratory diseases, making it a competitor to Liquidia.
Merck &
MRK
Mkt Cap318.55B
Merck & Co., Inc. offers a broad portfolio of drugs, including treatments for respiratory conditions, competing in the same space as Liquidia.
Pfizer
PFE
Mkt Cap169.83B
Pfizer develops and manufactures drugs and vaccines, including for respiratory diseases, positioning it as a competitor to Liquidia.
Biogen
BIIB
Mkt Cap32.96B
Biogen focuses on advanced therapies for serious diseases, including pulmonary conditions, making it a competitor in the same therapeutic area as Liquidia.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals is known for its innovative treatments in several areas, including respiratory diseases, competing with Liquidia's developments.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.04B
Teva Pharmaceutical Industries specializes in generic and specialty medicines, including for respiratory conditions, making it a competitor to Liquidia.
Novartis
NVS
Mkt Cap232.42B
Novartis focuses on a wide range of healthcare areas, including respiratory diseases, directly competing with Liquidia's therapeutic focus.

Analyst Ratings

30$Average Price Target
The highest estimate is $32.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Show more...
CEO
Neal Fowler
Employees
145
Country
US
ISIN
US53635D2027
WKN
000A2JRNS

Listings

XNAS
US
LQDA
F
DE
LT4.F